Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;33(3):e13380.
doi: 10.1111/dth.13380. Epub 2020 Apr 16.

Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

Affiliations
Review

Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

Robert A Schwartz et al. Dermatol Ther. 2020 May.

Abstract

A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. We delineate it as generalized pustular figurate erythema.

Keywords: COVID-19; DRESS syndrome; SARS-2; SARS-CoV-2; Stevens-Johnson syndrome; Sweet syndrome; acute generalized exanthematous pustulosis; coronavirus; drug rash; erythema multiforme; figurate erythema; hydroxychloroquine; toxic epidermal necrolysis; urticaria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Hydroxychloroquine‐induced GPFE with numerous nonfollicular pustules atop atypical targetoid plaques. GPFE, generalized pustular figurate erythema

Comment in

References

    1. Patel S, John AM, Handler MZ, Schwartz RA. The fixed drug eruptions: an update emphasizing the potentially lethal generalized bullous fixed drug eruption. Am J Clin Dermatol. 2020. 10.1007/s40257-020-00505-3 [Epub ahead of print]. - DOI - PubMed
    1. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis: a review and update. J Am Acad Dermatol. 2015;73:843‐848. - PubMed
    1. Miteva L, Kadurina M, Schwartz RA. Childhood acute generalized exanthematous pustulosis induced by oral ketoconazole. Acta Dermatovenerol Croat. 2020;18:267‐270. - PubMed
    1. Husain Z, Reddy BY, Schwartz RA. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome: part I: clinical perspectives. J Am Acad Dermatol. 2013;68:693‐705. - PubMed
    1. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II: management and therapeutics. J Am Acad Dermatol. 2013;68:709‐717. - PubMed

MeSH terms